429 related articles for article (PubMed ID: 24625457)
1. Plerixafor added to G-CSF-supported paclitaxel-ifosfamide-cisplatin salvage chemotherapy enhances mobilization of adequate numbers of hematopoietic stem cells for subsequent autografting in hard-to-mobilize patients with relapsed/refractory germ-cell tumors: a single-center experience.
Kosmas C; Athanasopoulos A; Dimitriadis G; Miltiadous C; Zilakos M; Lydakis D; Magiorkinis E; Gekas C; Daladimos T; Mylonakis N; Ziras N
Anticancer Drugs; 2014 Aug; 25(7):841-7. PubMed ID: 24625457
[TBL] [Abstract][Full Text] [Related]
2. Plerixafor mobilization of peripheral blood hematopoietic progenitors to support further high-dose chemotherapy cycles in a patient with germ-cell tumor relapsing after previous tandem high-dose chemotherapy and hematopoietic cell transplantation: report of a case.
Miltiadous C; Dimitriadis GK; Roditis P; Kosmas C
Anticancer Drugs; 2017 Feb; 28(2):237-241. PubMed ID: 27749622
[TBL] [Abstract][Full Text] [Related]
3. Myeloablative chemotherapy and autologous stem cell transplantation can lead to successful postengraftment mobilization of hematopoietic progenitors to support planned subsequent cycle(s) of high-dose chemotherapy and autografting in a patient with relapsed germ-cell tumor.
Fergadis E; Gavrielatou N; Skouteris N; Athanasopoulos A; Lianos E; Kosmas C
Anticancer Drugs; 2019 Feb; 30(2):205-208. PubMed ID: 30489289
[TBL] [Abstract][Full Text] [Related]
4. Plerixafor-aided Mobilization of Peripheral Blood Hematopoietic Stem Cells to Support Subsequent High-dose Chemotherapy After a Prior Autologous Transplant.
Fergadis E; Assi A; Kranidioti E; Kosma A; Karakosta M; Miltiadous C; Dimitriadis GK; Grivas A; Athanasopoulos A; Lianos E; Kosmas C
Clin Lymphoma Myeloma Leuk; 2020 Feb; 20(2):e50-e57. PubMed ID: 31884151
[TBL] [Abstract][Full Text] [Related]
5. Successful Mobilization of Autologous Hematopoietic Peripheral Blood Stem Cells after Salvage Chemotherapy in Patients with Low CD34 Blood Cell Counts.
Holmberg LA; Linenberger M; Connelly-Smith L
Transplant Cell Ther; 2022 Nov; 28(11):754-759. PubMed ID: 36002104
[TBL] [Abstract][Full Text] [Related]
6. Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial.
Nademanee AP; DiPersio JF; Maziarz RT; Stadtmauer EA; Micallef IN; Stiff PJ; Hsu FJ; Bridger G; Bolwell BJ
Biol Blood Marrow Transplant; 2012 Oct; 18(10):1564-72. PubMed ID: 22683613
[TBL] [Abstract][Full Text] [Related]
7. A prospective, multicenter study on hematopoietic stemcell mobilization with cyclophosphamide plus granulocyte colony-stimulating factor and 'on-demand' plerixafor in multiple myeloma patients treated with novel agents.
Mina R; Petrucci MT; Bonello F; Bongarzoni V; Saccardi R; Bertuglia G; Mengarelli A; Spadaro A; Lisi C; Curci P; Lemoli RM; Ballanti S; Floris R; Cupelli L; Tosi P; Olivieri A; Rota-Scalabrini D; Cangialosi C; Nozzoli C; Anaclerico B; Fazio F; Bruno B; Mancuso K; Corradini P; Milone G; Boccadoro M
Haematologica; 2024 May; 109(5):1525-1534. PubMed ID: 37981892
[TBL] [Abstract][Full Text] [Related]
8. Factors determining pbsc mobilization efficiency and nonmobilization following ICE with or without rituximab (R-ICE) salvage therapy for refractory or relapsed lymphoma prior to autologous transplantation.
Xia W; Ma CK; Reid C; Bai L; Wong K; Kerridge I; Ward C; Greenwood M
J Clin Apher; 2014 Dec; 29(6):322-30. PubMed ID: 24944079
[TBL] [Abstract][Full Text] [Related]
9. Plerixafor: A chemokine receptor-4 antagonist for mobilization of hematopoietic stem cells for transplantation after high-dose chemotherapy for non-Hodgkin's lymphoma or multiple myeloma.
Steinberg M; Silva M
Clin Ther; 2010 May; 32(5):821-43. PubMed ID: 20685493
[TBL] [Abstract][Full Text] [Related]
10. Salvage treatment with paclitaxel, ifosfamide, and cisplatin plus high-dose carboplatin, etoposide, and thiotepa followed by autologous stem-cell rescue in patients with relapsed or refractory germ cell cancer.
Rick O; Bokemeyer C; Beyer J; Hartmann JT; Schwella N; Kingreen D; Neureither S; Metzner B; Casper J; Wandt H; Hartmann F; Schmoll HJ; Derigs G; Gerl A; Berdel WE; Kanz L; Siegert W
J Clin Oncol; 2001 Jan; 19(1):81-8. PubMed ID: 11134198
[TBL] [Abstract][Full Text] [Related]
11. Bevacizumab/high-dose chemotherapy with autologous stem-cell transplant for poor-risk relapsed or refractory germ-cell tumors.
Nieto Y; Tu SM; Bassett R; Jones RB; Gulbis AM; Tannir N; Kingham A; Ledesma C; Margolin K; Holmberg L; Champlin R; Pagliaro L
Ann Oncol; 2015 Oct; 26(10):2125-32. PubMed ID: 26199392
[TBL] [Abstract][Full Text] [Related]
12. Plerixafor and granulocyte-colony-stimulating factor (G-CSF) in patients with lymphoma and multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy for autologous hematopoietic stem cell mobilization: the Austrian experience on a named patient program.
Worel N; Rosskopf K; Neumeister P; Kasparu H; Nachbaur D; Russ G; Namberger K; Witt V; Schloegl E; Zojer N; Linkesch W; Kalhs P; Greinix HT
Transfusion; 2011 May; 51(5):968-75. PubMed ID: 20880037
[TBL] [Abstract][Full Text] [Related]
13. Feasibility study of IL-11 and granulocyte colony-stimulating factor after myelosuppressive chemotherapy to mobilize peripheral blood stem cells from heavily pretreated patients.
Goldman SC; Bracho F; Davenport V; Slack R; Areman E; Shen V; Lenarsky C; Weinthal J; Hughes R; Cairo MS
J Pediatr Hematol Oncol; 2001; 23(5):300-5. PubMed ID: 11464987
[TBL] [Abstract][Full Text] [Related]
14. Experience with plerixafor for hematopoietic cell mobilization in nine patients with germ cell tumors.
Daphne O'Hara VJ; Karr AH; Srivastava S; Kiel PJ
Pharmacotherapy; 2014 Jan; 34(1):85-8. PubMed ID: 23864559
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of hematopoietic stem cell remobilization with plerixafor+G-CSF in adult patients with germ cell tumors.
Horwitz ME; Long G; Holman P; Libby E; Calandra GC; Schriber JR
Bone Marrow Transplant; 2012 Oct; 47(10):1283-6. PubMed ID: 22343676
[TBL] [Abstract][Full Text] [Related]
16. Combination chemotherapy containing mitoguazone, ifosfamide, methotrexate, etoposide (MIME) and G-CSF efficiently mobilize peripheral blood progenitor cells in heavily pre-treated relapsed lymphoma patients.
Aurlien E; Holte H; Kvaløy S; Jakobsen E; Rusten LS; Kvalheim G
Eur J Haematol Suppl; 2001 Jul; 64():14-20. PubMed ID: 11486395
[TBL] [Abstract][Full Text] [Related]
17. A risk-based approach to optimize autologous hematopoietic stem cell (HSC) collection with the use of plerixafor.
Abhyankar S; DeJarnette S; Aljitawi O; Ganguly S; Merkel D; McGuirk J
Bone Marrow Transplant; 2012 Apr; 47(4):483-7. PubMed ID: 21725372
[TBL] [Abstract][Full Text] [Related]
18. Cost and clinical analysis of autologous hematopoietic stem cell mobilization with G-CSF and plerixafor compared to G-CSF and cyclophosphamide.
Shaughnessy P; Islas-Ohlmayer M; Murphy J; Hougham M; MacPherson J; Winkler K; Silva M; Steinberg M; Matous J; Selvey S; Maris M; McSweeney PA
Biol Blood Marrow Transplant; 2011 May; 17(5):729-36. PubMed ID: 20813198
[TBL] [Abstract][Full Text] [Related]
19. High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Salvage Therapy of Relapsed/Refractory Germ Cell Tumors: A Single-Center Experience.
Yildiran Keskin GS; Erturk I; Aykan MB; Acar R; Dumludag A; Topal A; Koseoglu C; Kuzu OF; Ornek E; Karadurmus N
Oncol Res Treat; 2024; 47(6):262-272. PubMed ID: 38583428
[TBL] [Abstract][Full Text] [Related]
20. [Efficiency and safety analysis of Plerixafor combined with granulocyte colony-stimulating factor on autologous hematopoietic stem cell mobilization in lymphoma].
Ji MM; Shen YG; Gong JC; Tang W; Xu XQ; Zheng Z; Chen SY; He Y; Zheng X; Zhao LD; Zhao WL; Wu W
Zhonghua Xue Ye Xue Za Zhi; 2023 Feb; 44(2):112-117. PubMed ID: 36948864
[No Abstract] [Full Text] [Related]
[Next] [New Search]
